Our cutting-edge proprietary technology is the driving force behind our strong research and vaccine development pipeline, helping the global health community better prepare for and combat life-threatening infectious disease outbreaks.
OUR INNOVATIVE VACCINE TECHNOLOGY PLATFORM – ADVAC®
Our innovative vaccine technology platform – AdVac® – offers real hope for the accelerated development of vaccines and is designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks.
This is the same technology that was used in the development of our investigational Ebola vaccine, which has been deployed in the Democratic Republic of the Congo (DRC) and Rwanda, and was also used to construct our HIV, RSV and Zika vaccine candidates.
The SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® technology in an effort to help combat the current COVID-19 pandemic.
ADVAC® VIRAL VECTOR TECHNOLOGY
Adenoviruses are a group of viruses that cause the common cold - so they're good for transporting things into humans.
Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease.
|The AdVac® technology works by using an adenovirus as a vector (a carrier) of an antigen’s genetic code, to mimic components of a pathogen (a bacterium, virus, or other disease-causing organism). Antigens (components of a pathogen) are produced to mimic the pathogen, without causing severe disease.|
|When the body encounters the antigen the body will induce both a long-lasting humoral and cellular immune response against the antigen, by producing immune cells and antibodies.|
|In the future, if the body encounters the actual pathogen, the body will be able to respond faster and more effectively, as immune cells and antibodies specific to the pathogen will be rapidly produced in the body to prevent the pathogen from inducing disease.|
OUR VACCINE TECHNOLOGY IN ACTION
On March 30, 2020, Johnson & Johnson announced a lead vaccine candidate for COVID-19. The SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® technology that provides the ability to rapidly develop new vaccine candidates.
During the Ebola virus epidemic in West Africa, Janssen responded by accelerating Ebola virus vaccine development and scale up, resulting in the manufacturing of more than two million monovalent vaccine regimens in less than one year.